The statement, which was provided for a hearing examining the program, highlighted how the 340B program helps hospitals improve access to comprehensive healthcare services for more patients.
“Given the increasingly high cost of pharmaceuticals, the 340B program remains critical,” and scaling it back would have “devastating consequences for patients and communities,” the AHA said in the statement.
More articles on healthcare finance:
Hospitals’ uncompensated care costs fell by $7.4B last year
Subsidies are central part of PPACA’s success, GAO says
Details on Banner Health’s $86M facility in Colorado released
